Advertisement

Prostacyclin in Therapy of Vascular Disease

  • R. J. Gryglewski
  • A. Szczeklik
Part of the NATO ASI Series book series (NSSA, volume 95)

Abstract

In arteries of animals with experimental atherosclerosis (Gryglewski et al. 1978, DeGaetano et al. 1979, Larrue et al. 1980, 1982)and in arteries of humans with atherosclerosis (D’Angelo et al. 1978, Sinzinger et al. 1979) or with an exposure to risk factors (Silberbauer et al. 1979, Dadak et al. 1981) the generation of a prostacyclin-like activity is severely suppressed. On the other hand it has been recently reported that the urine excretion of prostacyclin metabolites is augmented in atherosclerosis. The validity of a conception that prostacyclin deficiency is associated with development of atherosclerosis depends on further analytical studies, however, the results of early experimental findings stimulated clinicians to use prostacyclin for treatment of arterial disease (Szczeklik et al. 1979). Irrespectively to a role that prostacyclin may play in pathogenesis of atherosclerosis, the drug itself has a potent platelet-suppressant and vasodilatory actions (Szczeklik et al.,1978). Fibrionolytic (Dembińska-Kieć et al. 1982) and cytoprotective (for ref. see Vane, 1983) properties of prostacyclin might be also of clinical importance.

Keywords

Peripheral Arterial Disease Retinal Vein Occlusion Central Retinal Vein Occlusion Acute Myocardial Infarction Patient Peripheral Arterial Disease Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Assai, J.P., Helg, C., VonderWeld, N. et al., 1980, Prostacyclin perfusions in diabetic peripheral arterial insufficiency, Diabetologia 19: 254.Google Scholar
  2. Belch, J.J.F., McArdle, B., Pollock, J.G., Forbes, C.D., McKay, A., Leiberman, P., Lowe, G.D.O. and Prentice, C.R.M., 1983a, Epoprostenoi (prostacyclin) and severe arterial disease, Lancet i: 315Google Scholar
  3. Belch, J.J.F., Drury, J.K., Capell, H., Forbes, C.D., Newman, P., McKenzie, F., Leiberman, P., Prentice, C.R.M., 1983b, Intermittent Epoprosenol (prostacyclin) infusion in patients with Raynaud’s syndrome, Lancet i: 313.Google Scholar
  4. Bergman,G., Daly, K., Atkinson, L., Rothman, M., Richardson, P.O., Jackson, G., Jewitt, D.E., 1981, Prostacyclin: haemodynamic and metabolic effects in patients with coronary heart disease, Lancet i: 596.Google Scholar
  5. Carlson,L.A. and Eriksson, I., 1973, Femoral artery infusion of prostaglandin E in severe periphe-ral vascular disease, Lancet i: 155.Google Scholar
  6. Chierchia, S., Patrono, C., Cia attoni, G., De Caterina, R., Cinotti, G.A., Distante, A. and Maseri, A., 1982, Effect of intravenous prostacyclin in variant angina, Circulation, 65: 470.PubMedCrossRefGoogle Scholar
  7. Dadak, C., Leithner, C., Silberbauer, K. and Sinzinger, H., Diminished prostacyclin formation in umbilical arteries of babies born to women who smoke, Lancet 1981, i:94Google Scholar
  8. Dadak, C., and Sinzinger, H., 1983, Therapie der schweren EPH-Gestose mit Prostacyclin. GYn. Rundschau 23: 225Google Scholar
  9. D’Angelo, V., Villa, S., Mysliwiec, M., Donati, M.B. and deGaetano, G., 1978, Defective fibrinolytic and prostacyclin-like activity in human atheromatous plaques. Thromb.Diath.Haemor. 39: 535.Google Scholar
  10. DeGaetano, G., Remuzzi, G., Myśliwiec, M., Donati, M.B. 1979, Vascular rostacyclin and plasminogen activator sctivity in experimental and clinical conditions of disturbed haemostasis or thrombosis. Haemostasis 8: 300.Google Scholar
  11. Dembińska-Kieć, A., Kostka-Trąbka, E. and Gryglewski, R.J., 1982, Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans, Thromb.Haemostas., 47: 190.Google Scholar
  12. Dembinska-Kiec, A., Zmuda, A., Grodzińska,L., Bieroń, K., Basista, M., Kędzior, A., Kostka-Trąka, E., Telesz, E., Żelazny, T.,1981, Increased platelet activity after termination of prostacyclin infusion into man. Prostaglandins 21: 827.Google Scholar
  13. Duadagni, D.N., Ikram, H., Maslowski, R., 1981, Haemodynamic effects of prostacyclin (PGI2) in pulmonary hypertension. Br. Heart J. 45: 385.Google Scholar
  14. Edhog,O., Henriksson.P., Wennmalm, A., 1983, Prostacyclin infusion in patients with acute myocardial infarction (preliminary report), New Eng1.J.Med. 308: 1032.Google Scholar
  15. Gryglewski, R.J., Dembińska-Kieć, A., Chytkowski, A., Gryglewska, T., 1978, Prostacyclin and thromboxane biosynthetic capacities of the heart, arteries and platelets at various stages of experimental atherosclerosis in rabbits, Atherosclerosis 31: 385.PubMedCrossRefGoogle Scholar
  16. Gryglewski, R.J., Nowak, S., Kostka-Trąbka, E., Kuśmiderski, J., Dembińska-Kieć, A., Bieroń, K., Basista, M., Błaszczyk, B., 1983, Treatment of ischaemic stroke with prostacyclin, Stroke 14: 197.PubMedCrossRefGoogle Scholar
  17. Hall, R.J. and Dewar, H.A., 1981, Safty of coronary arterial prostacyclin infusion, Lancet i: 949.Google Scholar
  18. Hallenbeck, J.M., 1984, The effect of prostacyclin, indomethacin and heparin on postischaemic nerve cell function, in: Clinical Trials of Prostacyclin, edited Ry R.J. Gryglewski, A. Szczeklik and J.C. McGiff, Raven Press, New York, in press.Google Scholar
  19. Henriksson, P., Edhog, O. and 4ennmalm, A., 1984, Limitation of myocardial infarction with prostacyclin - a double blind study, in: Clinical Trials of Prostacyclin editeR by R.J. Gryglewski, A. Szczeklik and J.C. McGiff, Raven Press, New York, in press.Google Scholar
  20. Hossman, V., Heinen, A., Auel, H., 1981, A randomized placebo-controlled trial of prostacyclin (PGI2) in peripheral arterial disease. Thromb.Res. 22: 481.PubMedCrossRefGoogle Scholar
  21. Huczyriski, J., Kostka-Trąbka, E., Sokołowska, W., Bieroń, K., Grodzińska, L., Dembińska-Kieć, A., Pykosz-Mazir, E., Peczak E. and Gryglewski, R.J.,1984 Prostacyclin in patients with completed ischaemic stroke - a controlled trial., in : Clinical Trials of Prostacvclin edited by R.O.. Gryglewski, A. Szczeklik and I.C. McGiff, Raven Press, New York, in press.Google Scholar
  22. Kadowitz, P.J., Spannhake, E,W., Levin, J.L., Hyman, A.L., 1980, Differential actions of the prostaglandins on the pulmonary vascular bed, in: Advances in Prostaglandin and Thromboxane Research. vol. 7, edited by B. Samuelsson, P.W. amwell and R. Paoletti, Raven Press, New York, pp. 731–743.Google Scholar
  23. Kaukinen, S., Pessi, T., Ylitalo, P., Krais T., and Vapaatalo, H., 1984, Clinical study on ZK 36374 - a new stable prostacyclin analogue for treatment of peripheral vascular disease, in: Clinical Trials of Prostacyclin, edited by R.J. Gryglewski, A. Szczeklik and J.C. McGiff, Raven Press, New York, in press.Google Scholar
  24. Larrue, J., Rigaud, M., Daret, D., Demond, J., Durand, J. Bricaud, H., 1980, Prostacyclin production by cultured smooth muscle cells from atherosclerotic rabbit aorta. Nature 285: 480.Google Scholar
  25. Larrue, J., Leroux, C., Daret,7., Bricaud, H., 1982 Decreased prostacyclin production in cultured smooth muscle cells from atherosclerotic rabbit aorta. Biochem.Biophys. Acta 710: 257.Google Scholar
  26. Leithner, C., Sinzinger, H., Schwartz, M., 1981, Treatment of chronic kidney transplant rejection with prostacyclin - reduction of platelet deposition in the transplant; prolongation of platelet survival and improvement of transplant function. Prostaglandins 22: 783.PubMedCrossRefGoogle Scholar
  27. Lock, J.E., 011ey, P.M., Coceani F., 1979, Use of prostacyclin in persistent fetal circulation, Lancet i: 1343.Google Scholar
  28. Machin, S.J.,,Defreyn, G., Chamone, D.A., Vermylen, J., 1981, Clinical infusions of prostacyclin in advanced arterial disease, in: Clinical Pharmacology of Prostacyclin, editedy by P. J. Lewis and J.M. 0-Grady, Raven Press, New York, pp. 173–175.Google Scholar
  29. Martin, J.F., Hamdy, N.A.T., Nicholl, J., Lewatae, N., Bergvall, U., Owen, P., Whittingtmn, D., 1984, Interim results from a double-blind controlled trial of prostacyclin in cerbral infarction, in: Clinical Trials of Prostacyclin, edited by R.J. Gryglewski, A. Szczeklik and J.C. McGiff, Raven Press, New York, in press.Google Scholar
  30. Niżankowski, R., Szczeklik, A., Królikowski, W., Bielatowicz J., Schaller, J., 1984, Prostacyclin for ischaemic ulcers in peripheral arterial disease - A random assignment, placebo-controlled study, in: Clinical Trials of Prostacyclin edited by R. Gryglewski, A. Szczeklik and J.C. McGiff, Raven Press, New York, in press.Google Scholar
  31. Olsson, A.G., 1980, Intravenous prostacyclin for ischaemic ulcers in peripheral artery disease, Lancet, ii: 1076.Google Scholar
  32. Olszewski, E., Sekuła, J., Kstka-Trąbka, E., Grodzińska L., Dembińska-Kiec, A., Bieroń, K., Basista, M. Kędzior, A. and R.J. Gryglewski, 1984, Prostacyclin in sudden deafness of vascular origin, in: Clinical Trials of Prostacyclin, edited by ff:J. Gryglewski, A. Sczeklik and J.C. McGiff, Raven Press, New York, in press.Google Scholar
  33. Pardy, B.J., Lewis, J.D, Eastcott, H.H.G., 1981, Preliminary experience with prostaglandins E1 and I2 in peripheral vascular disease, Surgery, 88: 826.Google Scholar
  34. Pickles, H. and O’Grady, J., 1982, Side effects occuring during administration of epoprostenol (prostacyclin, PGI2) in man, Br.J.Clin.Pharmac., 14: 177.Google Scholar
  35. Prentice, C.R.M. and Belch, J.J.F., 1984, Prostacyclin in Raynaud’s syndrome, in: Clinical Trials of Prostacyclin, edited brff.J. Gryglewski, A. Szczeklik and J.C. McGiff, Raven Press, New York in press.Google Scholar
  36. Rhodes, R.S. and Heard, S.E., 1983, Detrimental effects of high-dose prostaglandin E1 in the treatment of ischaemic ulcers, Surgery 93: 839.PubMedGoogle Scholar
  37. Rubin, L.J., Groves, B.M., Reeves J.T., Frosolono, Hendel, F., Cato, A., 1982, Prostacyclin-induced acute pulmonary vasodilatation in primary pulmonary hypertension, Circulation, 66: 334Google Scholar
  38. Silberbauer, K., Schernthaner, G., Sinzinger, H. Piza-Katzer, H., Winter, M., 1979, Decreased vascular prostacyclin in juvenile-onset diabetes, New Enq.O.Med. 300, 366.Google Scholar
  39. Silberbauer, K., Sinzinger, H., Puzengruber, C., 1982, Long-term prostacyclin-therapy in peripheral vascular disease–influence on some vascular and platelet regulating mechanisms, in: Prostaglandins in Clinical MedicineCardiovascular and Thrombotic Disorders, edited b7 K.K. Wu and P. Rossi, Yearbook Medical Publishers, Ne York, pp, 182–191.Google Scholar
  40. Sinzinger, H., Feigl, W., Silberbauer, K., 1979, Prostacyclin generation in atherosclerotic arteries, Lancet, ii: 469.Google Scholar
  41. Sinzinger, H., g H O’Grady, J., Cromwell, M., Hofer, R., 1983, Epoprostenol (prostacyclin) decreases platelet deposition on vascular prosthetic grafts. Lancet, i: 1275.Google Scholar
  42. Sinzinger, H., Silberbauer, K., Harsch, A•K., Gall, A., 1981, Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prosta-cyclin infusion in patients with peripheral vascular disease - a rebound phenomenon, Prostaglandins 21: 49.Google Scholar
  43. Szczeklik, A., Gryglewski, R.J., Niżankowski, R.,Musiał, J., Piętoń, R., Mruk, J., 1978, Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men. Pharmacol.Res.Commun. 10: 545.Google Scholar
  44. Szczeklik, A., Niiankowski, R., Skawinski,S., Szczeklik, J., Gluszko, P.Gryglewski, R.J., 1979, Successful therapy of advanced arterioslerosis obliterans with prostacyclin. Lancet i: 1111.Google Scholar
  45. Szczeklik, A., Niiankowski, R.,Szczeklik, J., Tabeau, J., Królikowski, W., 1984, Prostacyclin therapy in subgroups of patients with spontaneous angina, in: Clinical Trials of Prostacyclin, edited by Tl;J. Gryglewski, A. Szczekl k and J.C. McGiff, Raven Press, New York, in press.Google Scholar
  46. Szczeklik, A., Szczeklik, J., Niiankowski, R., 1981, Prostacyclin, nitroglycerin and effort angina. Lancet i: 1006.Google Scholar
  47. SzczekliT A., Szczeklik, J., Niżankowski, R., Głuszko, P., 1980 b, Prostacyclin for acute coronary insufficiency, Artery 8: 7.Google Scholar
  48. Szczeklik, A., Szczeklik, J., Niiankowski, R., 1980a, Prostacyclin for pulmonary hypertension, Lancet ii: 1076.Google Scholar
  49. Uchida, Y., Hanai, T., Hasegawa, K.,Kawamura, K., Oshima, T., 1982, Coronary recanalization induced by intracoronary administration of prostacyclin in patients with acute myocardial infarction. Circulation 66/II:Abstract No1045.Google Scholar
  50. Vane, J.R., Prostaglandins and the cardiovascular system, 1983, Br.Heart J. 49: 405PubMedCrossRefGoogle Scholar
  51. Watkins, W.D., Peterson, M.B., Crone, R.K., Shandon, D.C., Levine, L., 1980, Prostacyclin and prostaglandin E for severe idiopathic pulmonary artery hyper-teIsion, Lancet i: 1083.Google Scholar
  52. Yui, Y., Nakajima, F7, Kawai, C., Murakami, T., 1982, Prostacyclin therapy in patients with congestive heart failure, Am.J.Cardiol. 50: 320.Google Scholar
  53. Żygulska-Mach, H., Kostka-Trąbka, E., Mitoń, A., Gryglewski, R.J., 1980, Prostacyclin in central retinal vein occlusion, Lancet ii: 1075Google Scholar
  54. Żygulska-Mach, H., Kostka-Trąbka, E., Grodzinska, L., Bieron, K., Telesz, E., Gryglewski, R.J., 1984, Prostacyclin in therapy of central retinal vein occlusion, in: Clinical Trials of Prostacyclin, edited by R.J. Gryglewski, A. Szczeklik an.C. McGiff, Raven Press, New York, in press.Google Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • R. J. Gryglewski
    • 1
  • A. Szczeklik
    • 1
  1. 1.Department of Pharmacology and Department of MedicineN. Copernicus Academy of Medicine in CracowCracowPoland

Personalised recommendations